US EditionKelun-Biotech Announces Approximately US$250 Million Placement
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Placed 5,918,000 H shares on June 5, 2025, in Hong Kong, raising approximately US$250 million.
- The placement occurred due to strong investor demand that increased the deal size from an initial US$200 million target to US$250 million.
- The shares were priced at HK$331.8 each, representing a 7.58% discount to the last close and a 0.89% premium to the five-day average price.
- CEO Dr. Michael Ge expressed satisfaction with the ongoing backing from major current shareholders, as well as the involvement of prominent new investors.
- Kelun-Biotech plans to use the proceeds to advance research, clinical trials, registrations, manufacturing, commercialization, and global collaboration of its drug pipeline.
Insights by Ground AI
Does this summary seem wrong?
57 Articles
57 Articles
All
Left
8
Center
22
Right
3
Rutland Herald+56 Reposted by 56 other sources
Kelun-Biotech Announces Approximately US$250 Million Placement
CHENGDU, China, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital…
Coverage Details
Total News Sources57
Leaning Left8Leaning Right3Center22Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 24%
C 67%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
